文献速递前列腺癌

镭-223治疗转移性去势抵抗性前列腺癌骨转移的影像学反应:一项国际多中心数据库分析

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-02-28

本研究回顾性分析了8个中心、3个国家共130例接受镭-223治疗的转移性去势抵抗性前列腺癌(CRPC)患者的CT和骨闪烁显像反应。结果显示,治疗3个月和6个月时骨影像稳定者分别占74%(84/113)和94%(93/99),骨病灶数量增加者分别占26%(29/113)和6%(6/99);46%(57/124)的患者出现骨外影像学进展。作者认为镭-223治疗期间骨转移进展不常见,前3个月可能出现骨闪烁现象(疼痛和/或影像学),不应与进展混淆。

要点

  • 镭-223治疗3个月和6个月时骨影像稳定者分别占74%(84/113)和94%(93/99)。
  • 治疗期间骨转移相关疼痛一过性加重者占27%(33/124),疼痛改善者占49%(61/124)。
  • 46%(57/124)有CT资料的患者出现骨外影像学进展,作者建议在3剂和6剂后考虑CT检查。

核心结论

  • 镭-223治疗期间骨转移进展不常见,前3个月可能观察到骨闪烁现象(疼痛和/或影像学),不应与进展混淆。

研究设计与样本

  • 回顾性评估8个中心、3个国家共130例接受镭-223治疗的转移性去势抵抗性前列腺癌(CRPC)患者的CT和骨闪烁显像反应。

主要发现

  • 多数患者(84例,65%)在多西他赛之后接受镭-223治疗;有资料可查的99例患者中34例(34%)同时接受阿比特龙或恩扎卢胺治疗。
  • 54%(70例)患者完成了计划的6次镭-223注射。
  • 有资料可查的患者中,骨转移相关疼痛一过性加重者占27%(33/124),治疗期间骨转移相关疼痛改善者占49%(61/124)。
  • 治疗3个月和6个月时,骨影像显示疾病稳定者分别占74%(84/113)和94%(93/99)。
  • 与基线相比,3个月时骨病灶数量增加者占26%(29/113);与3个月相比,6个月时骨病灶数量增加者占6%(6/99);在有CT资料的患者中,46%(57/124)在3个月和/或6个月时出现骨外影像学进展。

临床怎么用

  • 作者认为镭-223治疗期间骨转移进展不常见,前3个月可能观察到骨闪烁现象(疼痛和/或影像学),不应与进展混淆。
  • 作者建议在镭-223治疗3剂和6剂后考虑进行CT扫描,以排除骨外疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment. METHODS: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries. RESULTS: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel. Thirty-four of 99 patients with available data (34%) received concomitant abiraterone or enzalutamide. A total of 54% (n=70) patients completed the planned six injections of radium-223. In patients with available data, a transient increase in bone metastases-related pain was observed in 27% (n=33/124) and an improvement of bone metastases-related pain on treatment with radium-223 was noted in 49% of patients (n=61/124). At 3 and 6 months of treatment with radium-223, bone imaging showed stable disease in 74% (n=84/113) and 94% of patients (n=93/99) with available data, respectively. An increase in the number of bone lesions was documented at 3 months compared with baseline in 26% (n=29/113) and at 6 months compared with 3 months in 6% of patients (n=6/99), respectively. Radiological extraskeletal disease progression occurred in 46% of patients (n=57/124) with available CT data at 3 and/or 6 months. CONCLUSIONS: Progression of bone metastases during radium-223 therapy is uncommon. A bone flare (pain and/or radiological) may be noted during the first 3 months, and should not be confused with progression. Imaging by CT scan should be considered after three and six doses of radium-223 to rule out extraskeletal disease progression.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Keizman D, Fosboel MO, Reichegger H, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis. 2017. PMID: 28244493. doi:10.1038/pcan.2017.6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。